Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.

Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death.

Autorentext
Dr. Imteyaz Qamar is working as an assistant professor at School of biotechnology, Gautam Buddha University, Greater Noida, India. His area on interest is Stress biology, and Cancer Genetics

He earned his Ph.D. in Molecular Endocrinology from Chonnam National University, South Korea with an emphasis on gene regulation and physiological function of an androgen receptor corepressor-19kD using mice model. He has written various manuscripts, grants, progress reports, pre-IND protocols, animal protocols and published in well reputed international journals. He has also received various awards such as Brain Korea-21 Best Research presenter award 2007, Bharath Vikas award 2016, Young Scientist Award 2017 & 2019, STE meritorious award 2019 etc. He serves as a member of editorial boards of various peer reviewed journals. He is also a member of the endocrinology society, United States of America (USA). Prof. Pawan Kumar Maurya is Dean, School of Life Long Learning & Head of Department of Biochemistry, Central University of Haryana, India. He has done a PhD from the University of Allahabad (A Central University), India & post-doctoral training from Universidade Federal de Sao Paulo-UNIFESP, Brazil; Taipei Medical University (TMU) and National Taiwan University (NTU), Taiwan. He has more than 14 years of teaching and research experience. He is working on biochemical diagnostics, nanomedicine, and clinical biochemistry. He has published over 75 research articles in reputed journals. He has also edited of six books published from Elsevier, USA and Springer-Nature, Singapore. He is recipient of prestigious fellowships: Science without Borders (Government of Brazil) and National Science Council, Taiwan.

Inhalt

1. Preface
   
   2. Overview of changes in the Cardiovascular system
   3. Cardiovascular Disease in cancer survivors: Risk and management
   4. Recent trends in Cancer Immunotherapy: Pathways and inhibitors
   5. Stroke risk assessment and Atrial fibrillation in cancer patients
   6. Biochemistry of Biomarkers in Cardiotoxicity induced by chemotherapeutic drugs
   7. Cardio-toxic effects of Tyrosine kinase inhibitors directed against VEGFR
   8. Critical insights into Cardiotoxicity of Anthracyclines
   9. Noninvasive Cardiovascular imaging techniques
   10. Radiotherapy induced( RIDH) Cardiovascular risk
   11. Cardiovascular complication from cancer therapy
   12. Novel Anticancer drugs related to Cardiotoxicity
   13. Principles of cardiovascular rehabilitation
   14. Hematopoietic stem cell transplantation